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Abstract: The outcome of congenital fibrinogen defects (CFD) is often unpredictable. Standard co-
agulation assays fail to predict the clinical phenotype. We aimed to assess the pheno- and genotypic 
associations of thrombin generation (TG) and ROTEM in CFD. We measured fibrinogen (Fg) activ-
ity and antigen, prothrombin fragments F1+2, and TG by ST Genesia® with both Bleed- and Throm-
boScreen in 22 patients. ROTEM was available for 11 patients. All patients were genotyped for fi-
brinogen mutations. Ten patients were diagnosed with hypofibrinogenemia, nine with dysfibrino-
genemia, and three with hypodysfibrinogenemia. Among the 17 mutations, eight were affecting the 
Fg γ chain, four the Fg Bβ chain, and five the Fg Aα chain. No statistical difference according to the 
clinical phenotypes was observed among FGG and FGA mutations. Median F1+2 and TG levels were 
normal among the different groups. Fg levels correlated negatively with F1+2 and peak height, and 
positively with lag time and time to peak. The pheno- and genotypes of the patients did not associ-
ate with TG. FIBTEM by ROTEM detected hypofibrinogenemia. Our study suggests an inverse link 
between low fibrinogen activity levels and enhanced TG, which could modify the structure–func-
tion relationship of fibrin to support hemostasis. 
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1. Introduction 
Congenital fibrinogen disorders (CFD) are rare disorders affecting either the quantity 
(afibrinogenemia and hypofibrinogenemia) or the quality (dysfibrinogenemia) or both 
(hypodysfibrinogenemia) of fibrinogen (Fg) [1]. Hypofibrinogenemia and dysfibrino-
genemia are the most frequent types of CFD, characterized by decreased levels of both Fg 
activity and antigen in the former, and discrepant levels of dysfunctional Fg in the latter. 
They usually result from heterozygous mutations affecting one of the three fibrinogen 
genes (i.e., FGA, FGB, or FGG) [2]. Hypodysfibrinogenemia is rarely reported. The diag-
nosis is based not only on a disproportional decrease of activity and antigen Fg levels, but 
also on specific molecular patterns [3]. 
The clinical course of CFD is often unpredictable. The clinical manifestations are very 
heterogeneous, from absence of symptoms to major bleeding or thrombosis (either arterial 
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or venous) and pregnancy-related complications [4,5]. Moreover, asymptomatic individ-
uals at the time of diagnosis may carry a lifetime risk of adverse outcomes. Although the 
diagnosis of most CFD is usually quite straightforward based on standard coagulation 
assays [6,7], these conventional tests fail to predict the clinical phenotype. Especially, the 
dysfunctional/abnormal Fg structure in dysfibrinogenemia is poorly assessed by standard 
coagulation assays. According to the recommendations of the Factor XIII and Fibrinogen 
Subcommittee of the Scientific Standardization Committee of the ISTH, the classification 
of CFD should be based on both the clinical phenotype and fibrinogen levels. In addition, 
specialized research laboratories should complete the fibrinogen work-up, providing in-
sights into the properties of the fibrinogen variants [8].  
During the last few years, a growing interest has evolved in the use of global hemo-
stasis assays to measure the dynamics of the entire clotting and fibrinolysis process and 
to study the risks of bleeding and thrombosis under various clinical settings [9,10]. Until 
now, few attempts have been made to characterize the usefulness of thromboelastography 
in patients with CFD [11–13]. The influence of fibrinogen level on thrombin generation 
(TG) has also been investigated [14]. However, data in the setting of CFD—notably qual-
itative fibrinogen disorders—have limited to very few case reports [15]. 
Lately, a new TG analyzer (ST Genesia®, Stago) has been released as the first fully 
automated TG method for clinical routine laboratories. ST Genesia® offers a set of rea-
gents balanced for sensitivity to procoagulant and anticoagulant protein deficiencies [16]. 
We aimed to assess the clinical outcome by studying TG by ST Genesia® and ROTEM 
in relation to various phenotypes, and to explore whether the clinical phenotypes are as-
sociated with genetic mutations. 
2. Results 
A total of 22 patients, 12 from Finland and 10 from Switzerland, were included. The 
median age of patients was 43.5 years (range 21–83 years). Most of the patients were fe-
male (77.3%). Fourteen patients were unrelated.  
The clinical features, genotypes and Fg levels of the patients are presented in Table 
1. 
Table 1. Clinical manifestations, genotypes, and phenotypic characteristics according to traditional fibrinogen assays. 
 Patient Age Gender Phenotypes Fg Act Fg Ag Type Gene Mutation Family Members 
Family 1 
HEL 1.1 72 Female Asymptomatic 1.3 1.3 Hypo 1 FGG, exon 8 
het Thr303Pro and het 
Asp327His 
Thrombosis 
HEL 1.2 24 Male Asymptomatic 0.7 0.7 Hypo 1 FGG, exon 8 
het Thr303Pro and het 
Asp327His 
 
HEL 1.3 48 Female Thrombosis 1.0 1.2 Hypo 1 FGG, exon 8 




HEL 2.1 82 Male Thrombosis 1.2 2.5 Dys 2 FGG, exon 8 het Tyr306Cys Thrombosis 
HEL 2.2 58 Male Asymptomatic 1.6 2.5 Dys 2 FGG, exon 8 
homozygous 
Tyr306Cys  
HEL 2.3 83 Male Asymptomatic 1.7 3.5 Dys 2 FGG, exon 8 het Tyr306Cys  
Family 3 
HEL 3.1 40 Female 
Bleeding and 
thrombosis 
1.0 1.7 Hypo 1 FGG, exon 8 




HEL 3.2 30 Female Bleeding <1 0.7 Hypo 1 FGG, exon 8 




HEL 4 35 Female Asymptomatic 0.8 1.8 Hypodys 3 FGG, exon 9  het Trp395Leu Thrombosis 
HEL 5 38 Female Asymptomatic <1 2.6 Dys 2 FGG, exon 9  het c.1283-1284 del TG Thrombosis 
HEL 6 43 Female Asymptomatic 1.9 2.4 Dys 2 FGA, exon 2 het Leu28Pro NA 
HEL 7 47 Female Bleeding <1 1.0 Hypo 1 FGG, exon 9 het Thr397Ile Bleeding  
GEN 1 37 Female Bleeding 0.6 2.4 Dys 2 FGG  Arg301His Bleeding 




GEN 3 49 Female Bleeding 0.7 2.1 Dys 2 FGA Arg35His Bleeding 
GEN 4 30 Male Asymptomatic 0.7 1.4 Hypo 1 FGB Thr407Met Bleeding 
GEN 5 51 Male Asymptomatic 0.5 2.8 Dys 2 FGA Arg38Gly Asymptomatic 
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GEN 6 44 Male Asymptomatic 1.1 1.2 Hypo 1 FGG Arg375Trp Asymptomatic 
GEN 7 57 Female 
Bleeding and 
thrombosis 
1.1 1.8 Hypodys 3 FGB Arg285Leu Bleeding 
GEN 8 31 Male Asymptomatic 0.4 0.4 Hypo 1 FGA 11kb del Asymptomatic 
GEN 9 53 Female Asymptomatic 0.6 3.1 Dys 2 FGA Arg35His NA 
GEN 10 21 Female Bleeding 0.9 1.0 Hypo 1 FGB Arg294Ser Asymptomatic 
1 Hypofibrinogenemia, 2 Dysfibrinogenemia, 3 Hypodysfibrinogenemia. 
Nine patients were diagnosed with hypofibrinogenemia based on concordant Fg ac-
tivity and antigen levels (ratios > 0.7), with median Fg activity level of 0.8 g/L (range 0.45–
1.0 g/L) and median Fg antigen level of 1.0 g/L (range 0.40–1.2 g/L). Ten patients were 
diagnosed with dysfibrinogenemia based on discordant Fg activity and antigen levels (ra-
tios <0.7), with median Fg activity level of 0.9 g/L (range 0.40–1.40 g/L) and median Fg 
antigen level of 2.40 g/L (range 1.80–3.10 g/L). In three patients, a definitive diagnosis of 
hypodysfibrinogenemia was confirmed upon genetic analysis. Their median Fg activity 
level was 0.8 g/L (range 0.70–1.08 g/L) and median Fg antigen level was 1.60 g/L (range 
1.40–1.80 g/L). Bleeding tendency was classified with a bleeding score >3, which occurred 
in 5/22 (22.7%) patients, including three hypofibrinogenemia and two dysfibrinogenemia 
patients. Bleeding symptoms included menorrhagia (n = 5), vaginal bleeding during preg-
nancy (n = 1), bleeding after injury (n = 1), hemarthrosis (n = 1), postsurgical hemorrhage 
(n = 3). Two patients had only thrombotic complications (9%). One female with hypofi-
brinogenemia (HEL 1.3), obesity, and type 2 diabetes experienced a provoked deep ve-
nous thrombosis (DVT) and was treated with warfarin for three months. A patient with 
dysfibrinogenemia (HEL 2.1), obesity and dyslipidemia developed unprovoked pulmo-
nary embolisms (PE) and DVT of the upper limb and was commenced on lifelong antico-
agulant therapy with warfarin. Two patients had both bleeding and thrombotic compli-
cations. One female with hypodysfibrinogenemia (GEN 7) suffered from provoked PEs 
following a hysterectomy due to menorrhagia. She was treated by three months of low 
molecular weight heparin (LMWH). Another female with hypofibrinogenemia (HEL 3.1) 
and obesity experienced DVT of the right lower limb during intake of oral contraceptive 
at the age of 18, and later at the age of 36 two unprovoked DVTs, one of the left lower 
extremity, and three months later left iliofemoral DVT despite warfarin therapy. For the 
latest, she underwent iliac vein stenting under fibrinogen supplementation (Riastap, CSL 
Behring) and received a long-term antithrombotic treatment with LMWH and aspirin. She 
also suffered from menorrhagia but gave birth three times without major bleeding com-
plications. She received LMWH prophylaxis throughout her pregnancies and pospartum 
up to 6 weeks. Thirteen patients were asymptomatic, of which 4/22 (18.2%) had hypofi-
brinogenemia, 7/22 (31.8%) dysfibrinogenemia, and 2/22 (9%) hypodysfibrinogenemia 
(Table 1). 
Genetic analyses identified 14 missense mutations in 19 patients from 14 unrelated 
families, and three deletions in the remaining three patients. As shown in Table 1, almost 
all Finnish patients had missense mutations clustered in exons 2, 8, or 9 of FGG. The same 
double heterozygous FGG mutations, most likely carried on the same chromosome, 
p.Thr303Pro and p.Asp327His were discovered in two unrelated families (families 1 and 
3, n = 5). In family 2, the FGG p.Tyr306Cys mutation was identified in both heterozygous 
and homozygous form. Interestingly, the patient HEL 2.2 with the homozygote form of 
the mutation was asymptomatic, while the patient 2.1 with the heterozygote form had 
thrombotic complications. More heterogeneous distribution was observed in the Swiss 
patients. Four had mutations affecting the Fg Aα chain, four the Fg Bβ chain and three the 
Fg γ chain. Of note, the asymptomatic patient GEN 6 had a mutation in FGG exon 8 
p.Arg375Trp which is the causative mutation of fibrinogen Aguadilla, associated with a 
fibrinogen storage disease [17]. No statistical difference according to the clinical pheno-
types was observed among FGG and FGA mutations. 
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2.1. Thrombin Generation 
TG variables by ST Genesia® (STG-BLS and STG-TS) are reported as normalized (Ta-
ble 2) and absolute values (Figures 1–3). Patients 2.1 and 3.1 with long-term anticoagula-
tion and antiplatelet therapy were excluded from this study. None of the patients received 
oral contraception or hormonal therapy during the TG studies. 
Table 2. Mean normalized TG variables with STG-BLS and STG-TS in the absence of thrombomodulin according to clinical 
and laboratory phenotypes. 
STG-BLS Normalized Lag Time, Ratio (Range) ETP, % (Range) Peak Height, % (Range) Time to Peak, Ratio (Range) 
Hypofibrinogenemia (n = 8)  1.2 (0.9–1.4) 82.7 (41.6–101.5) 88,5 (30.6–113.2) 1.1 (1.0–1.4) 
Dysfibrinogenemia 
(n = 8) 
1.1 (0.8–2.0) 80.4 (49.2–111.2) 81.4 (46.6–104.5) 1.1 (0.9–1.7) 
Hypodys-fibrinogenemia (n = 3) 1.0 (1.0–1.6) 83.0 (49.2–105.0) 81.4 (39.2–121.7) 1.1 (1.0–1.3) 
Reference range * 0.9–1.3 57–114 51–99 0.9–1.3 
STG-TS-TM Normalized Lag Time, Ratio (Range) ETP, % (Range) Peak Height, % (Range) Time to Peak, Ratio (Range) 
Hypofibrinogenemia (n = 8)  1.1 (0.9–1.3) 79.0 (46.3–90.5) 75.1 (32.7–90.0) 1.2 (1.1–1.7) 
Dysfibrinogenemia (n = 8) 1.1 (0.8–2.2) 65.0 (48.1–96.5) 62.2 (33.7–78.8) 1.2 (0.9–2.0) 
Hypodys-fibrinogenemia (n = 3) 1.1 (1.1–1.5) 80.8 (52.9–83.1) 65.5 (28.8–89.1) 1.2 (1.1–1.6) 
Reference range * 1.0–1.3 59–99 45–102 1.0–1.5 
* Reference range as according to the literature [16]. 
 
Figure 1. Mean TG variables with STG-BLS (bleedscreen) according to clinical and laboratory phenotypes. TG values are 
shown for 19 patients as follows: asymptomatic n = 13; bleeding n = 4, thrombosis n = 2; hypofibrinogenemia n = 8; dys-
fibrinogenemia n = 8 and hypodysfibrinogenemia n = 3. 




Figure 2. Mean TG variables with STG-TS (thromboscreen) according to clinical phenotype and the supplementation of 
TM. TG values are shown for 19 patients as follows: asymptomatic n = 13; bleeding n = 4, thrombosis n = 2; hypofibrino-
genemia n = 8; dysfibrinogenemia n = 8; and hypodysfibrinogenemia n = 3. 
 
Figure 3. Mean TG variables with STG-TS (thromboscreen) according to laboratory phenotype and the supplementation 
of TM. TG values are shown for 19 patients as follows: asymptomatic n = 13; bleeding n = 4, thrombosis n = 2; hypofibrin-
ogenemia n = 8; dysfibrinogenemia n = 8; and hypodysfibrinogenemia n=3. 
All median TG levels were within the normal reference range [16]. The inter-individ-
ual variation was up to 6-fold for peak height and up-to 5-fold for ETP among patients 
with STG-TS in the presence of thrombomodulin (TM). Variations were dependent on the 
clinical phenotype or Fg levels. The largest CV was observed for the peak height among 
asymptomatic patients and dysfibrinogenemia (6-fold and 5-fold as compared to 3-fold 
variation in normal donors).  
In STG-BLS, lag time correlated positively with Fg activity (r = 0.6, p = 0.03), the peak 
height and ETP negatively with fibrinogen activity (r = −0.6, p = 0.03 and r = −0.7, p < 0.0001, 
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respectively; Figure 4). In STG-TS with TM, there was a positive correlation between lag 
time, time to peak and Fg activity (r = 0.6, p < 0.002 and r = 0.5, p < 0.01) and a negative 
correlation between both ETP and Fg activity (r = −0.5, p = 0.03, and r = −0.5 and p = 0.02). 
However, the subgroup analysis according to the type of CFD and the clinical phenotype 
did not reveal any difference between the groups nor statistical difference between TG 
variables, clinical phenotype, type of CFD, and presence of TM (Figures 1–3; data shown 
as absolute values).  
 
Figure 4. Correlation of TG variables with STG-BLS (bleedscreen) with fibrinogen activity. The data are shown TG values 
are shown for 19 patients as follows: asymptomatic n = 13; bleeding n = 4, thrombosis n = 2; hypofibrinogenemia n = 8; 
dysfibrinogenemia n = 8; and hypodysfibrinogenemia n = 3. 
There was no correlation among all the variables tested when comparing dysfibrin-
ogenemic mutations affecting the thrombin binding site at the N-terminal end of the fi-
brinogen Aα chain (FGA exon 2) to mutations affecting the end-to-end alignment of fi-
brinogen or fibrin molecules in assembling polymers (FGG exon 8). 
2.2. In Vivo Thrombin Generation 
F1+2 fragment levels varied between 82 and 552 pM (reference 69–229 pM), indicat-
ing normal to somewhat increased in vivo TG (data not shown). The inter-individual var-
iation was up to 7-fold among the patients. We demonstrated a negative correlation be-
tween F1+2 and both Fg antigen (r = −0,3, p < 0.006) and activity (r = −0.8, p = < 0.0001) 
levels (Figure 5). We further demonstrated a negative correlation between F1+2 and lag 
time by both STG-BLS (r = −0.3, p < 0.0003) and STG-TS in the absence of TM (r = −0.24, p 
< 0.001). The subgroup analysis according to CFD and clinical phenotype did not reveal 
any difference between the groups (Figure 6).  
  




Figure 5. Correlation of F1+2 levels with Fibrinogen activity and antigen. Data are shown for 20 patients as follows: asymp-
tomatic n = 13; bleeding n = 5, thrombosis n = 2; hypofibrinogenemia n = 9; dysfibrinogenemia n = 8 and hypodysfibrino-
















































Figure 6. Mean F1+2 levels according to the clinical and laboratory phenotypes. F1+2 values are 
shown for 20 patients as follows: asymptomatic n = 13; bleeding n = 5, thrombosis n = 2; hypofi-
brinogenemia n = 9; dysfibrinogenemia n = 8; and hypodysfibrinogenemia n = 3. 
2.3. ROTEM 
ROTEM analysis was carried out in 11 patients (7 hypo- and 5 dysfibrinogenemia, all 
from Finland) using the standard reagents. In hypofibrinogenemia, CT and MCF were 
markedly abnormal (Figure 7A). Median CT in hypofibrinogenemia compared with dys-
fibrinogenemia patient was 233 s (range 81–5414 s) vs. 55 s (range 50–132) (p = 0.0303). 
Median CT in hypofibrinogenemia was 76% prolonged as compared with dysfibrino-
genemia. Median MCF in hypofibrinogenemia compared with dysfibrinogenemia patient 
was 4 mm (range 0–6 mm) vs. 13 mm (range 11–24 mm) (p= 0.0022), corresponding to 69%, 
lowered value in dysfibrinogenemia. MCF by FIBTEM correlated with Fg antigen (r = 0.6, 
p = 0.006) but not with activity (r = −0.2, p = 0.4). Moreover, there was a statistical difference 
among the patient’s clinical phenotype for the FIBTEM CT (p = 0.0003) 
Median CT and MCF were all normal by EXTEM, INTEM, and APTEM. Median MCF 
in hypofibrinogenemia compared with dysfibrinogenemia patients was significantly re-
duced in all other ROTEM tests as follows: EXTEM hypofibrinogenemia 49 mm (below 
normal range) vs dysfibrinogenemia 61 mm (p = 0.003; normal range 58–63 mm), INTEM 
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hypofibrinogenemia 48 mm (below normal) vs. dysfibrinogenemia 60 mm (p = 0.004; nor-
mal range 59–64 mm) and APTEM hypofibrinogenemia 52 mm vs. dysfibrinogenemia 62 
mm (p = 0.007; normal range 50–72 mm (Figure 7B). We observed a strong uniform nega-
tive correlation between Fg activity and in overall MCFs by EXTEM (r = −0.6, p = 0.004), 
INTEM (r = −0.6, p = 0.004) and APTEM (r = −0.7, p = 0.002). A weaker negative correlation 
between Fg antigen and MCF by EXTEM (r = −0.5, p = 0.01), INTEM (r = −0.5, p = 0.01), and 




Figure 7. ROTEM profiles according to clinical and laboratory phenotypes. (A). FIBTEM CT and MCF are shown for 110 patients as 
follows: asymptomatic n = 7; bleeding n = 2, thrombosis n = 2; dysfibrinogenemia n = 6 and dysfibrinogenemia n = 5. * CT was 
markedly prolonged in hypo- in comparison with dysfibrinogenemia (p = 0.0303). **Fibrin polymerization capacity (clot firmness) 
in FIBTEM was decreased (MCF ≤ 6mm) in hypofibrinogenemia as compared with dysfibrinogenemia (p = 0.0022). (B). EXTEM, 
INTEM, and APTEM MCF are shown for 11 patients as follows: asymptomatic n = 7; bleeding n = 2, thrombosis n = 2; dysfibrino-
genemia n = 6; and dysfibrinogenemia n = 5 MCF was markedly decreased in hypo- in comparison with dysfibrinogenemia in EX-
TEM (* p = 0.003), INTEM (** p = 0.004), and APTEM (*** p = 0.007). 
3. Discussion 
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In this study, we investigate for the first time the TG by ST Genesia® in CFD and 
correlated biological and clinical phenotypes with ROTEM parameters. We observed a 
significant correlation between Fg levels and TG, both with ST Genesia® in vitro and pro-
thrombin fragments F1+2 reflecting FXa in vivo. An important association between the 
laboratory phenotype of CFD and FIBTEM was picked up.  
The final fibrin clot has a highly heterogeneous structure, which is determined by 
both genetic and environmental factors [18]. Lower Fg concentrations increase bleeding 
risks due to formation of thicker fibrin fibers which are more susceptible to fibrinolysis. 
In contrast, abnormal structure of fibrin paradoxically increases thrombotic risk by im-
pairing fibrin degradation by plasmin or facilitating clot fragmentation [18,19] and even 
enhancing TG due to poorly polymerizing fibrin [20]. Therefore, TG and other coagulation 
activation markers, such as prothrombin activation fragments, fibrin structure and conse-
quences of the fibrinolytic system are of particular interest in CFD [21].  
To our knowledge, this is the largest study reporting data on thrombin generation in 
CFD and the first study to assess the value of the ST Genesia® device in the context of 
CFD. TG seems to be affected by the abnormal fibrin structures as Fg activity levels corre-
lated with most TG variables. One of the most important questions is whether ST Gene-
sia® can help to identify the dysfibrinogenemia patients at the highest risk of thrombotic 
complications. Indeed, it could be that patients with the most decreased Fg activity have 
significantly higher ETP and peak height, and shortened lag time when challenged to low 
concentration of TF. Furthermore, in vivo TG was enhanced in patients with lower Fg 
levels, as occurs in a rare metabolic genetic disorder of lysinuric protein intolerance, LPI 
[21]. However, the clinical phenotype failed to be associated with TG variables. A more 
global approach taking also into account the fibrin clot structure including the capacity to 
make cross links may help to determine the heterogeneity of the clinical phenotype. 
Only a few clinical studies explored non-conventional assays, such as thromboelas-
tography (TEG) or ROTEM in predicting the clinical course of CFD. In these studies, TEG 
variables were affected by the causative mutations, but TEG failed to predict adverse 
events in most of the patients [11]. In one study, abnormal TEG results in non-pregnant 
women associated with an increased risk of obstetric complication during pregnancy [12]. 
One study on ROTEM showed that patients with dysfibrinogenemia have much higher 
median values of MCF than patients with hypodysfibrinogenemia [22], which may possi-
bly reflect differences in the natural history of these disorders. This is in line with our 
observation as we found markedly abnormal median CT and CFT readings by FIBTEM in 
hypofibrinogenemia as compared to dysfibrinogenemia. Moreover, MCFs were signifi-
cantly lower in the hypofibrinogenemia group than in dysfibrinogenemia according to all 
routine ROTEM tests used and correlated with Fg levels in all. Among them, FIBTEM 
MCF is of particular value to measure the contribution of Fg to the clot firmness, since 
cytochalasin D is first used to inactivate the platelets in the sample [23,24]. Here, on the 
other hand, the role of platelets remains obscure. Lower MCF readings in the patients such 
may reflect an impaired fibrin polymerization capacity. So far, no correlation between 
thromboelastometry and clinical phenotypes was demonstrated. Instead, in our subgroup 
analysis, we observed an association between the clinical phenotype of CFD and FIBTEM. 
Larger prospective studies are warranted to further validate and explore the mechanisms 
underlying these findings. 
The spectrum of molecular abnormalities in CFD is broad, resulting in several sub-
types of fibrinogen disorders with specific biological and clinical features [17]. Only a few 
fibrinogen variants are definitely associated with a clinical course. Thrombosis-related 
dysfibrinogenemia leads to a strong thrombotic phenotype, which usually is present in 
young adult with a thrombotic familial history [25]. A few fibrinogen mutations, clustered 
in exons 8 and 9 of FGG, cause fibrinogen deposit in endoplasmic reticulum, which in turn 
can give rise to liver failure [26]. However, in dysfibrinogenemia genotype cannot predict 
the bleeding risk. As confirmed by our observations, the individual range of TG variables 
was high without any correlation according to the site of fibrinogen mutation (FGA; Aα 
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chain vs. γ chain). It is likely that besides fibrinogen variants, other relatively common 
genetic polymorphisms or epigenetics in coagulation and fibrinolytic pathways may affect 
the fibrin clot structure and therefore act as modifiers of the blood clot function in dys-
fibrinogenemia. 
Our study is limited by the patient numbers, being too small to allow any further 
conclusions on the clinical phenotype vs. thrombin generation. Nevertheless, it presents a 
cohort of 22 CFD patients, as higher numbers are difficult to reach considering the rela-
tively low prevalence of the disease and pre-analytical requirements for the TG assay.  
In conclusion, our data suggests that ROTEM has a high sensitivity towards detection 
of hypofibrinogenemia. While the assessment of ROTEM, MCF, and especially FIBTEM 
may help to discriminate patients with hypo- or dysfibrinogenemia, its effectiveness in 
predicting the clinical phenotypes has to be confirmed on larger groups of patients. Our 
study suggests an inverse link between low fibrinogen activity levels and enhanced TG, 
likely including poor fibrin build-up which could modify the structure–function relation-
ship of fibrin to support hemostasis. These similarities have been observed in other clinical 
inherited conditions such as FXIII deficiency and LPI with enhanced TG but overly ex-
pressed fibrinolysis. 
4. Materials and Methods 
Our study was conducted in accordance with the Declaration of Helsinki and ap-
proved by the relevant local institutional ethical committees (191/13/03/01/2014; 24 Sep-
tember 2014). All patients consented to take part in the study. The study included patients 
and their relatives with confirmed diagnosis of CFD from Helsinki, Finland (Coagulations 
Disorders Unit, Comprehensive Cancer Center, Helsinki University Hospital) and from 
Geneva, Switzerland (Division of Angiology and Hemostasis, University Hospitals of Ge-
neva) between 2018 and 2020. CFD was classified based on the activity and antigen levels 
of Fg and genotype according to the International Society of Thrombosis and Hemostasis 
(ISTH) classification [8]. Symptoms of bleeding and/or thrombosis were recorded from 
the medical files. The bleeding score was evaluated by the ISTH bleeding assessment tool 
[27]. 
4.1. Blood Sampling  
Fasting peripheral venous blood samples were collected under stable conditions at a 
time remote from acute infections, bleeds or surgeries, between 8–10 am into vacutainer 
tubes containing: (1) EDTA to measure blood cell counts and hemoglobin levels, and (2) 
sodium citrate (109 mM sodium citrate, 3.2%, BD-Plymouth) for routine coagulation, TG 
and ROTEM. 
4.2. Coagulation Studies 
Citrated blood samples were centrifuged to isolate plasma and frozen in aliquots at 
−70 °C, if not tested immediately. Plasma levels of functional Fg were measured by the 
Clauss method using the HemosIL Fibrinogen activity (IL QFA Thrombin) on an ACL Top 
Analyzer or Multifibren U (Siemens, Marburg, Germany) on a BCS® XP coagulometer. 
Levels of total Fg antigen were measured by a latex immunoassay (Liaphen Fibrinogen, 
Hyphen BioMed, Neuville sur Oise, France) on a BCS® XP coagulometer (Siemens, Ger-
many). 
Prothrombin time (PT; Owren method, Axis-Shield, Oslo, Norway), activated partial 
thromboplastin time (APTT; Actin FSL reagent) and thrombin time (Hemoclot Thrombin 
Time, Hyphen BioMed, France) were assessed in citrated plasma on an ACL Top Analyzer 
analyzer. Prothrombin fragments (F1+2) were measured by an enzyme immunoassay (En-
zygnost® F1+2, monoclonal, Siemens Healthcare Diagnostics, Marburg, Germany.  
4.3. DNA Preparation and Genetic Analysis  
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Genomic DNA was extracted from fresh blood samples using standard procedures. 
Fibrinogen mutation screening was performed by PCR amplification of fibrinogen coding 
sequences and intron-exon junctions followed by Sanger sequencing (samples until 2019) 
or by whole exome sequencing performed at the Health 2030 Genome Centre at Campus 
Biotech, Geneva using Twist Core +Refseq Exome reagents. Variant calling was filtered 
for a panel of genes of the coagulation and fibrinolytic pathways, including the fibrinogen 
genes. Variant analysis was performed using the Ensembl Variant Effector Predictor 
(VEP) tool: http://www.ensembl.org/Homo_sapiens/Tools/VEP. Mutations were con-
firmed by polymerase chain reaction (PCR) amplification of by sequencing as previously 
described [28]. According to guidelines of the Human Genome Variation society, muta-
tions are reported with nucleotides numbered from the A in the ATG (Met) initiator codon 
and amino acids numbered from Met 1 [29]. 
4.4. Thrombin Generation  
TG was measured in platelet-poor (PPP) plasma by using the novel, fully-automated 
ST Genesia® Analyzer (Diagnostica Stago S.A.S., Asnières-sur-Seine, France), which is 
based on the reference Calibrated Automated Thrombogram method [14]. PPP was pre-
pared by double centrifugation at 2500 g for 10 min at room temperature within 2 h of 
blood collection [14]. The assessment is based on measurement of fluorophore ami-
nomethylcoumarin (AMC) generation, after adding a standard amount of human recom-
binant tissue factor and synthetic phospholipids to induce TG in the test plasma. AMC 
generation is monitored every 15–20 s at 450 nm. All measurements were carried in du-
plicate by using two types of reagents: the STG®-BleedScreen (STG-BLS, Stago, Asnières-
sur-Seine, France and the STG®-ThromboScreen (STG-TS, Stago, Asnières-sur-Seine, 
France). TG with the STG-BLS assay was triggered by a mixture of procoagulant phos-
pholipids and low picomolar level of human tissue factor (TF), balanced for sensitivity to 
procoagulant factor deficiencies while minimizing contact activation. TG with the STG-TS 
assay was initiated by a mixture of procoagulant phospholipids and medium picomolar 
level of human TF in the presence or absence of TM, balanced for sensitivity to deficiencies 
in natural anticoagulants, without interfering contact activation. Since the addition of corn 
trypsin inhibitor upon blood collection did not make a difference in the data we are re-
porting the results obtained only in the citrated samples. 
We followed endogenous thrombin potential (ETP), peak thrombin (peak height), lag 
time, and time to peak. Both absolute and normalized values of each TG parameter is 
provided. Normalization of each TG parameter is based on a reference plasma for each 
test aiming to reduce the interlaboratory variability as well as the variability between dif-
ferent measurement runs. We used standard human plasma in addition to the reference 
plasma TG levels provided by the manufacturer to assess TG in normal plasma. 
4.5. Rotational Thromboelastometry  
Thromboelastometry in whole blood was measured within 2 h of blood collection by 
ROTEM [30]. The standard INTEM, EXTEM, FIBTEM, and APTEM activation methods 
were performed by automated pipette program. We analyzed clotting time (CT, s) and 
maximum clot firmness (MCF, mm). The reference ranges were: FIBTEM CT 46–84s and 
MCF 6–21mm, INTEM CT 161–204s and MCF 51–69 mm; EXTEM CT 50–80s, and MCF 
55–72mm; APTEM CT 41–80s, and MCF 52–71 mm.  
4.6. Prothrombin Fragments F1+2 
Circulating prothrombin fragments (F1+2) were measured in plasma with Enzyg-
nost® ELISA (Siemens). The manufacturer’s reference ranges (5th to 95th percentiles) are 
69–229 pmol/L. 
4.7. Statistical Analysis 
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The recorded data are expressed as median and range. The significance of difference 
between two distinct data groups was examined with Mann–Whitney tests. The signifi-
cance of difference between more groups was estimated by one-way analysis of variance 
(ANOVA). The correlation between two variables was measured using Spearman r test. 
Calculations were performed with Prism 7.0 or 9.0 (GraphPad Software, La Jolla, CA, 
USA).  
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